Key points are not available for this paper at this time.
Aim: Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer characterized by the absence of estrogen receptors, progesterone receptors, and HER2 expression, making it challenging to treat with targeted therapies. Olaparib, a PARP inhibitor, has shown promise in treating TNBC, particularly in patients with BRCA1 or BRCA2 mutations. This study aims to elucidate the metabolic pathways affected by olaparib in TNBC using bioinformatics analysis. Material and Method: Gene expression profiles of TNBC cell lines treated with olaparib were analyzed to identify differentially expressed genes. Pathway enrichment analysis was conducted using KEGG databases to determine the biological pathways influenced by olaparib treatment. Network analysis further identified key regulatory nodes and interactions within these pathways. Results: The results revealed significant alterations in metabolic pathways, DNA damage repair, and apoptosis, highlighting the multifaceted impact of olaparib on TNBC cells. Conclusion: This comprehensive bioinformatics approach provides insights into the molecular mechanisms of olaparib's action and identifies potential targets for combination therapies to enhance treatment efficacy. Experimental validation of these findings is essential to confirm the clinical relevance and to develop more effective therapeutic strategies for TNBC.
Yalda Hekmatshoar (Tue,) studied this question.